The current treatment landscape of mHSPC

Treatment Options for mHSPC

Key Themes:

• Current 2025 guidelines recommend ADT with intensification.
• Multiple intensification options include abiraterone, darolutamide, and docetaxel.
• Key clinical trials include ARANOTE, ARASENS, and TITAN.
• All studies demonstrate survival benefit and delayed disease progression with intensification.

Key Points for Physicians:

• ADT monotherapy is no longer the standard of care.
• Multiple evidence-based intensification options exist.
• Selection can be tailored based on patient characteristics and preferences.
• All intensification approaches demonstrate benefit over ADT alone.

Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.

Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.